| Mrs Sarah Elizabeth James, MS CCC-SLP | |
|
3801 Summitview Ave, Yakima, WA 98902-2794 | |
| (509) 985-8420 | |
| Not Available |
| Full Name | Mrs Sarah Elizabeth James |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3801 Summitview Ave, Yakima, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114453297 | NPI | - | NPPES |
| 14009063 | Other | WA | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL60751801 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Sarah Elizabeth James, MS CCC-SLP 3801 Summitview Ave, Yakima, WA 98902-2794 Ph: (509) 985-8420 | Mrs Sarah Elizabeth James, MS CCC-SLP 3801 Summitview Ave, Yakima, WA 98902-2794 Ph: (509) 985-8420 |
News Archive
A team of researchers from Vanderbilt University's schools of Law, Medicine and Management has received a five-year research grant from the Agency for Healthcare Research and Quality of the Department of Health and Human Services to develop and test "safe harbor" standards of care based on scientific evidence.
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania into the TOBA II clinical on October 19, 2015. This trial is to assess the safety and efficacy of a vascular implant for the treatment of dissections (tearing in the artery wall) that occur following balloon angioplasty (PTA) of the main artery in the leg.
Some viruses' ability to exploit the human body's own defenses to increase their replication may be both a blessing and curse, according to the findings of a study conducted by researchers at the Johns Hopkins Bloomberg School of Public Health.
The U.S. Food and Drug Administration (FDA) on the 25th of June 2018 approved Epidiolex oral solution that is essentially cannabidiol or the active component of marijuana or cannabis. As of now the drug is approved for use in two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome. The approval comes for individuals over two years of age.
Cholera has been confirmed as the cause of death of 16 persons on a remote island in Papua New Guinea which is close to Australia's maritime border. The first case was detected on Daru Island in Western Province three weeks ago. Since then 12 adults and 4 children have died, and 320 others have been treated for the infection.
› Verified 9 days ago
Chelsea Hach, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 303 S 12th Ave, Yakima, WA 98902 Phone: 509-453-8248 Fax: 509-248-9012 | |
Suzanne Marie Rettig, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 110 S 9th Ave, Yakima, WA 98902 Phone: 509-575-5068 Fax: 509-577-4604 | |
Ms. Nicole Elizabeth Kristek, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1807 Pickens Loop, Yakima, WA 98908 Phone: 206-334-7007 | |
Shelby Griffin, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 N 4th Ave, Yakima, WA 98902 Phone: 509-573-5060 | |
Julie Durnan, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 610 S 15th Ave, Yakima, WA 98902 Phone: 509-823-9653 | |
Ms. Joann Thomas-delp, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 N 16th Ave, Yakima, WA 98902 Phone: 509-573-1737 |